Adenoid Cystic Carcinoma Market to Grow with a CAGR of 5.42% through 2028
Rising advancements in precision medicine is expected
to drive the Global Adenoid Cystic Carcinoma Market growth in the forecast
period, 2024-2028.
According to TechSci Research report, “Adenoid
Cystic Carcinoma Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2028”, the Global Adenoid Cystic Carcinoma Market
stood at USD 218.06 Million in 2022 and is anticipated to grow with a CAGR of 5.42%
in the forecast period, 2024-2028. The Global Adenoid Cystic Carcinoma Market is a
dynamic and evolving sector within oncology, marked by advances in treatment
options and diagnostic approaches. One of the most significant drivers of growth in the
ACC market is the advent of precision medicine. ACC tumors are known for their
heterogeneity, meaning they can vary greatly in their molecular characteristics
even within the same subtype. Precision medicine techniques, such as molecular
profiling and genetic testing, enable healthcare providers to identify specific
genetic mutations and biomarkers unique to each patient's tumor. This
information allows for the development of personalized treatment plans tailored
to target the precise molecular drivers of the disease. As a result, patients
are more likely to receive therapies that are effective and have fewer side
effects, significantly improving their quality of life.
The emergence of targeted therapies has revolutionized
the treatment of ACC. Unlike traditional chemotherapy, which often affects both
cancerous and healthy cells, targeted therapies are designed to specifically
target the molecular abnormalities driving cancer growth. In the ACC market,
several targeted therapies have shown promise in clinical trials. For example,
drugs targeting genetic mutations such as MYB-NFIB fusion have demonstrated
encouraging results in ACC patients. These therapies not only offer a more
effective approach to treatment but also contribute to the growing optimism
surrounding ACC management.
Immunotherapies have become a game-changer in the
fight against cancer, and ACC is no exception. These therapies work by
harnessing the body's immune system to identify and attack cancer cells. While
ACC has historically been considered an immunologically "cold" tumor,
recent research has unveiled potential targets for immunotherapies in ACC
patients. Clinical trials exploring the efficacy of immune checkpoint
inhibitors and other immunomodulatory agents in ACC are underway. The introduction
of immunotherapies into the ACC market holds promise for patients who may not
respond well to traditional treatments.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Adenoid Cystic Carcinoma Market”
The Global Adenoid Cystic Carcinoma Market is
segmented into Drug Class, Treatment, distribution channel, regional
distribution, and company.
Based on the Drug Class, the Tyrosine Kinase
Inhibitors (TKIs) emerged as the dominant segment in the global market for
Global Adenoid Cystic Carcinoma Market in 2022. Also, compared to traditional
cytotoxic drugs, TKIs often have a more favorable safety and side effect
profile. This improved safety margin can lead to better patient compliance and
prolonged treatment durations, which can be crucial in managing slow-growing
tumors like ACC. TKIs have found use in a variety of cancers, not just ACC. Their success
in treating other malignancies has accelerated research into their potential
benefits for ACC, driving demand within the market.
Based on the Treatment, the Surgery emerged as the
dominant player in the global market for Global Adenoid Cystic Carcinoma Market
in 2022. Surgery offers the best chance for local control of ACC tumors. ACC
often presents slow-growing, localized masses, particularly in the head and
neck region where it is most common. Surgical resection allows for the removal
of the tumor, which is crucial in preventing its growth and spreading to
adjacent tissues. In many cases, surgery is performed with curative intent,
especially when ACC is diagnosed in its early stages. Complete surgical
resection, where the entire tumor is removed with negative margins, can provide
long-term disease control and potentially a cure for the patient. Surgery provides
the opportunity for histological assessment of the tumor. Examining the removed
tissue under a microscope can help pathologists determine the tumor's subtype
and grade, which is crucial for treatment planning and prognosis. In cases
where complete resection is not possible, surgery may still play a role as part
of a multimodal treatment approach. After surgery, radiation therapy or other
adjuvant therapies may be employed to target any remaining cancer cells.
Based on the Distribution Channel, the Hospital
pharmacies emerged as the dominant player in the global market for Global Adenoid
Cystic Carcinoma Market in 2022. Hospital pharmacies are an integral part of
healthcare institutions. They are physically located within hospitals or
medical centers, ensuring close coordination between healthcare providers and
pharmacists. This proximity allows for immediate access to ACC treatments
following diagnosis and treatment planning. ACC treatments often require
specialized medications, including chemotherapy, targeted therapies, and
supportive care drugs. Hospital pharmacies are equipped to stock and dispense
these specialized medications, ensuring that patients receive the precise
treatments prescribed by their healthcare providers.
Hospital pharmacists work closely with the healthcare
team to monitor patient responses to treatments, manage potential side effects,
and make real-time adjustments to medication regimens. This level of clinical
oversight is crucial in ACC treatment, where personalized care is essential.
North America emerged as the dominant player in the
global Adenoid Cystic Carcinoma Market
in 2022, holding the largest market share. North America boasts a highly
developed healthcare infrastructure, including state-of-the-art medical
facilities, research institutions, and cancer centers. This advanced
infrastructure enables the early detection, diagnosis, and treatment of ACC,
attracting patients from both within and outside the region. The region is a
leader in research and development investments in the field of oncology.
Pharmaceutical companies, academic institutions, and government agencies in
North America invest significantly in cancer research, including ACC. This
commitment to research fosters innovation in diagnostics and therapeutics for
ACC, driving market growth. North America has well-established cancer awareness
and screening programs, which contribute to the early diagnosis of ACC. Early
detection is crucial for effective treatment, and these programs play a vital
role in identifying ACC cases at earlier, more treatable stages.
Major companies operating in Global Adenoid
Cystic Carcinoma Market are:
- Ayala
Pharmaceuticals
- Amgen Inc.
- CureVac AG
- Elevar Therapeutics
- Actuate Therapeutics
- Prelude Therapeutics
- Merck Sharp &
Dohme Corp.
- Elly Lilly and
Company
- Celgene Corporation
- OncoMed
Pharmaceuticals
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The Global
Adenoid Cystic Carcinoma (ACC) Market anticipates significant growth in the
coming years, primarily driven by advancements in precision medicine tailored
to the genetic diversity of ACC subtypes. These targeted treatment approaches
offer new hope for ACC patients, as therapies become more effective and less
burdensome. Additionally, the rising adoption of immunotherapies, which harness
the body's immune system to combat ACC, is reshaping the treatment landscape
and contributing to market expansion. Patient advocacy groups and increased
awareness efforts are raising funds and supporting research, further driving
innovation in ACC care. Moreover, collaboration among pharmaceutical companies,
research institutions, and healthcare providers is accelerating the development
of novel treatments.” said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based management consulting firm.
“Adenoid Cystic Carcinoma Market - Global Industry Size, Share, Trends,
Opportunity, and Forecast, 2018-2028 Segmented By Drug Class (Cytotoxic Drugs,
Tyrosine Kinase Inhibitors, Monoclonal Antibodies, Others), By Treatment
(Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy), By Distribution
Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) By Region
and Competition”, has evaluated the future growth potential of Global
Adenoid Cystic Carcinoma Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Adenoid
Cystic Carcinoma Market.
Contact
Mr. Ken
Mathews
708 Third
Avenue,
Manhattan, NY,
New York –
10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com